translational research

Alevian is a preclinical-stage biotech developing regenerative therapeutics that target biological mechanisms promoting repair and regeneration. Its lead program, ALE-001, is an engineered recombinant form of GDF11 designed to treat acute ischemic stroke by reducing inflammation, promoting neovascularization, stimulating neurogenesis, and improving functional recovery, with a treatment window extending to 3 days. ALE-001 is progressing toward first-in-human studies, with additional programs in intracerebral hemorrhage, traumatic brain injury, chronic str

biologics developmentGDF11 signaling pathway researchpreclinical research

Aqualung Therapeutics is a clinical stage immunotherapeutics company developing targeted therapies for inflammatory injury, fibrosis, and vascular leak. Its eNamptor platform includes ALT-100, a humanized monoclonal antibody designed to neutralize eNAMPT, along with complementary biomarker tools to support precision guided treatment.

biomarker developmentclinical developmenttherapeutic development

Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Its approach enables selective modulation of disease-causing proteins. The company is advancing multiple programs, including its lead asset ATV-1601, an oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT), and a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms. It has built a versatile discovery platform that identifies functional pockets across protein classes, with an internal focus on rare

allosteric drug discoverycheminformaticsclinical developmentCMCDMPKmedicinal chemistryRegulatory Affairs

Attana AB is a Swedish life science company that provides the life science community with analytical instruments and services for bioanalysis. Its proprietary biosensor technology measures molecular interactions in real time in biologically relevant environments such as blood, plasma, living cells and tissue, helping drug developers validate, select and optimize drug candidates for Phase I and Phase II studies. The company also offers contract research (CRO) services and diagnostics through Attana Diagnostics and Attana Virus Analytics (AVA).

antibody developmentbiosensor technologycell-based assaysdrug discovery and developmentimmunogenicity studiesinteraction analysiskinetic analysislabel-free analysisvaccine development

Auni Therapeutics is a biotech company developing a next-generation immunotherapy for food allergies, with a platform designed to expand across multiple allergens and deliver durable clinical benefits. The company is led by a multidisciplinary executive team of physician-scientists, serial entrepreneurs, and operational leaders focused on translating next-generation immunology into therapeutic assets.

clinical strategydrug discovery and developmentimmunotherapy development

Blackfin Bio is a UK-based biotechnology spinout company from the University of Sheffield, founded in November 2023, committed to developing next-generation gene therapies. Its mission is to bring hope, healing and life-changing benefits to patients living with rare and other diseases of the Central Nervous System, including SPG47. The company aims to accelerate the clinical development of gene therapies into life-changing treatments.

clinical developmentgene therapy development

CasNx is developing CRISPR treatments that act on donor organs outside the body before transplantation, starting with human kidney tissue research. The company brings CRISPR engineering and transplant medicine together to develop gene therapies for organs before transplantation, exploring the window when a donated organ is outside the body before it reaches its recipient.

CRISPR engineeringdeliveryDNA-guided CRISPR platformorgan perfusiontransplant medicine

Celularity Inc. (NASDAQ: CELU) is a clinical and commercial stage biotechnology company developing and commercializing off-the-shelf placental-derived allogeneic cell therapies and advanced biomaterial products targeting age-related diseases and serious unmet medical needs. Its platform includes mesenchymal-like adherent stromal cells (MLASCs), Natural Killer (NK) cells, and engineered T cells including CAR-T cells. It operates a purpose-built 150,000 sq ft facility in Florham Park, NJ.

biobankingbiosourcingCDMOcell selectioncellular medicine manufacturingcryopreservationin-house cGMP manufacturing

Compvide is a biotechnology company specializing in functional complement assay development, clinical sample analysis, and complement diagnostics. Its proprietary CIMED diagnostic platform provides pathway-specific ELISA kits for complement activity measurement and pharmacodynamic drug monitoring. The company supports pharmaceutical, biotech, academic, and diagnostics partners with pathway-specific functional assays spanning the classical, lectin, and alternative complement pathways.

clinical sample analysiscomplement assay developmentELISA-based diagnosticspharmacodynamic monitoring

Corvidane is a privately held life sciences company developing novel therapeutic approaches for cardiometabolic disease, including atherosclerosis and metabolic dysfunction associated steatohepatitis (MASH). Its lead programme, CVMB-216, is a patented orally administered, multi-pathway therapeutic that activates a spectrum of clinically validated targets spanning lipid metabolism, inflammation and fibrosis. The company advances programmes through structured preclinical development toward regulated clinical pathways and pursues two indications for FDA app

clinical developmentdrug developmentpreclinical developmentprocess scale-uptherapeutic development

Freedom Biosciences is a biotechnology platform developing next-generation neuropsychiatric therapeutics, including ketamine-based and 5ht2a-based treatments for mental health and substance use disorders. Co-founded by Dr. John Krystal and Dina Burkitbayeva, it develops combination therapies and has a pipeline of clinical and preclinical programs including FREE-001 for treatment-resistant depression and FREE-002 for comorbid major depressive disorder and substance use disorder.

clinical developmentdrug discovery platformregulatory strategy